Actively Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Led by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Updated on 2026-03-23
387
Participants Needed
11
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
CONDITIONS
Official Title
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically documented locally advanced unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
- Measurable disease by RECIST v1.1
- ECOG performance status 0-1
You will not qualify if you...
- Malignancy within the last 2 years as specified in the protocol
- Untreated brain metastases
- Known hypersensitivity to BBO-11818 or its excipients
- Other exclusion criteria as specified in the protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, United States, 90025
Actively Recruiting
2
University of California San Diego Moores Cancer Center
San Diego, California, United States, 92037
Actively Recruiting
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
4
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
5
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
6
Columbia University Irving Medical Center
New York, New York, United States, 10032
Actively Recruiting
7
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, United States, 75230
Actively Recruiting
8
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
9
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
10
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
11
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
T
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
14
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here